Aequus Pharmaceuticals Inc (AQS) - Total Assets
Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) holds total assets worth CA$196.16K CAD (≈ $141.90K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Aequus Pharmaceuticals Inc book value and equity for net asset value and shareholders' equity analysis.
Aequus Pharmaceuticals Inc - Total Assets Trend (2013–2024)
This chart illustrates how Aequus Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Aequus Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Aequus Pharmaceuticals Inc's total assets of CA$196.16K consist of 35.2% current assets and 64.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 6.3% |
| Accounts Receivable | CA$49.30K | 6.2% |
| Inventory | CA$37.80K | 4.7% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Aequus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aequus Pharmaceuticals Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aequus Pharmaceuticals Inc's current assets represent 35.2% of total assets in 2024, a decrease from 98.0% in 2013.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2024, down from 92.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.2% of total assets.
Aequus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Aequus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Aequus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.05 | 7.20 |
| Quick Ratio | 0.03 | 0.03 | 6.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-6.89 Million | CA$-6.28 Million | CA$2.38 Million |
Aequus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Aequus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.39 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -26.3% |
| Total Assets | CA$800.28K |
| Market Capitalization | $479.73K USD |
Valuation Analysis
Below Book Valuation: The market values Aequus Pharmaceuticals Inc's assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aequus Pharmaceuticals Inc's assets decreased by 26.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aequus Pharmaceuticals Inc (2013–2024)
The table below shows the annual total assets of Aequus Pharmaceuticals Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$800.28K ≈ $578.91K |
-26.32% |
| 2023-12-31 | CA$1.09 Million ≈ $785.76K |
-35.78% |
| 2022-12-31 | CA$1.69 Million ≈ $1.22 Million |
-61.10% |
| 2021-12-31 | CA$4.35 Million ≈ $3.15 Million |
+38.71% |
| 2020-12-31 | CA$3.13 Million ≈ $2.27 Million |
+87.41% |
| 2019-12-31 | CA$1.67 Million ≈ $1.21 Million |
-16.22% |
| 2018-12-31 | CA$2.00 Million ≈ $1.44 Million |
-25.28% |
| 2017-12-31 | CA$2.67 Million ≈ $1.93 Million |
+32.92% |
| 2016-12-31 | CA$2.01 Million ≈ $1.45 Million |
-17.27% |
| 2015-12-31 | CA$2.43 Million ≈ $1.76 Million |
-33.72% |
| 2014-12-31 | CA$3.67 Million ≈ $2.65 Million |
+986.74% |
| 2013-12-31 | CA$337.33K ≈ $244.02K |
-- |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more